Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?
- PMID: 39477632
- DOI: 10.1016/j.jacc.2024.09.015
Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?
Keywords: aficamten; cardiac myosin inhibitor; hypertrophic cardiomyopathy; left ventricular outflow tract obstruction; septal myectomy; septal reduction therapies.
Conflict of interest statement
Funding Support and Author Disclosures Dr Ammirati has received a grant from the Italian Ministry of Health (GR-2019-12368506) related to his work as Principal Investigator of the investigator-driven MYTHS trial, and a grant from Italian Ministry of Health and NextGenerationEU (PNRR-MAD-2022-12376225); and has served as a consultant for Kiniksa, AstraZeneca, and Cytokinetics. Dr Gallone has reported that he has no relationships relevant to the contents of this paper to disclose.
Publication types
LinkOut - more resources
Full Text Sources